



PRESS RELEASE

26 September 2025 – 7:30 AM

Plan-Les-Ouates & Zurich (CH) – Antwerp (BE)

Gimv and EGS Beteiligungen reinforce strategic support for Spineart with CHF 25 million capital increase to accelerate global growth

Spineart (www.spineart.com), a global medtech innovator in advanced spine surgery solutions, today announces a CHF 25 million capital increase backed by its long-standing investors Gimv and EGS Beteiligungen (EGSB). This new funding will fuel Spineart's next phase of profitable growth, enabling the company to advance its innovation pipeline and strengthen its global footprint in delivering better outcomes for spine surgery patients.

Spineart's profitable growth strategy is anchored in a comprehensive portfolio of cutting-edge technologies designed to make spine surgery safer, more efficient and more effective. With a strong focus on clinical outcomes, the company is expanding across Europe and the United States with ongoing regulatory submissions to the U.S. FDA for its **BAGUERA® C cervical disc prosthesis**. Strategic partnerships and investments in digital navigation and robotics are also enhancing Spineart's innovation capabilities, adding a transformative dimension to its future growth.

Spineart currently employs over 360 professionals worldwide and is projected to reach revenues of approximately EUR 140 million in 2025, reflecting five consecutive years of growth at an average annual rate of +16%. With a recently opened modern production facility in Reignier, France, the company is well-positioned to meet the rising global demand for its advanced spine surgery solutions.

*"This investment represents a major milestone in Spineart's profitable growth journey," said **Jerome Trividic, CEO of Spineart**. "Over the past years, we've made targeted strategic investments in product innovation, robotics, regulatory expansion in Europe and the United States and manufacturing, that are now coming to fruition. With the continued support of Gimv and EGSB, we are well-positioned to scale globally, deliver innovative, differentiated technologies and reinforce our commitment to surgical excellence and improved patient outcomes."*

*"Our sustained commitment to Spineart reflects our strong belief in the company's innovation capabilities in the field of spine surgery and its international growth potential," said **Bart Diels and Gautier Lefebvre, respectively Managing Partner and Partner Healthcare of Gimv**. "This investment fits perfectly with the ambition of our Healthcare platform to support pioneering companies shaping the future of healthcare and demonstrates our ability to successfully do it on the long run. This additional investment underlines Gimv's accelerated growth ambitions. The total cumulative investment in the company makes it one of Gimv's five largest investments."*

*"As an investor in Spineart since 2020, we are very pleased with its strong development and remain fully committed to supporting this outstanding company," said **Dominik Sauter, former Managing Director and current Senior Advisor, and Christian Pfab, Member of the Executive Committee of EGSB**. "Our additional investment underscores our dedication to fostering entrepreneurship and helping innovative businesses scale and thrive internationally."*



About Spineart

Spineart is a recognized leader in spine surgery innovation focused on elevating the standard of spinal care for patients across the world. Spineart supports spine surgeons in over 60 markets, operating a broad commercial portfolio of patented, clinically validated solutions which incorporate advances in minimally invasive surgery, motion preservation technologies, 3D-printed implants and streamlined instrumentation.

www.spineart.com

For further information about this press release, please contact:

press@spineart.com

About Gimv

Gimv is a European investment company, listed on Euronext Brussels and a member of the Euronext BEL ESG Index. With over 45 years' experience in private equity, Gimv currently manages an investment portfolio of around EUR 2 billion. The portfolio contains about 60 portfolio companies, with combined turnover of EUR 4.5 billion and more than 20,000 employees.

As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial, innovative companies with high growth potential and supports them in their transformation into market leaders. Gimv's five investment platforms are Consumer, Healthcare, Life Sciences, Smart Industries and Sustainable Cities. Each platform works with an experienced team across Gimv's home markets of Benelux, France and DACH, supported by an extended international network of experts.

www.gimv.com

For further information about this press release, please contact:

Bart Diels, Managing Partner – Head of Healthcare

bart.diels@gimv.com

+32 3 290 21 58

About EGS Beteiligungen

EGS Beteiligungen AG (EGSB) is the investment company of the Ernst Göhner Foundation, dedicated to long-term investments in businesses with a strong Swiss connection. Its diversified portfolio includes anchor shareholdings in selected listed companies, majority and qualified minority interests in privately held firms, as well as growth capital for late-stage start-ups. Headquartered in Zurich, Switzerland, EGSB combines financial strength with entrepreneurial expertise to create sustainable value and serve as a reliable partner for its portfolio companies and co-investors.

www.egs-beteiligungen.ch

For further information about this press release, please contact:

Christian Pfab, Member of the Executive Committee

christian.pfab@egs-beteiligungen.ch

+41 44 250 75 09